ADmit Therapeutics, S.L. is a spin-off from the Bellvitge Biomedical Research Institute (IDIBELL), and focused on the development and commercialization of a novel Alzheimer's disease (AD) early detection technology.
Our diagnostic test represents the determination of biomarkers non-related with β-amyloid nor tau.
Our findings may become a pool of biomarkers very useful for the detection of patients at early stages of AD.
CO-FOUNDER Ramón ReñéCHIEF MEDICAL OFFICER
MD, PhD in Medicine and Surgery
(Autonomous University of Barcelona) Jordi GascónCHIEF SCIENTIFIC OFFICER
MD in Medicine and Surgery
(Autonomous University of Barcelona)
By continuing to use this website, you consent cookies being installed on your browser. More information on our Cookies Policy